News Tag: mfn-ci-insider

The CEO of SpectraCure increases his shareholding through MK Capital

SpectraCure CEO Masoud Khayyami has, through his company MK Capital Invest, on November 8th bought 10 000 shares in SpectraCure. The shares were purchased at a rate of SEK 8.20 per share, corresponding to a transaction of SEK 82 000. The transaction was made on Aktietorget, according to the Financial Supervisory Authority (sv Finansinspektionen) transparency […]

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope